Clinical and immunological evaluation of zoledronate-activated Vgamma9gammadelta T-cell-based immunotherapy for patients with multiple myeloma.

@article{Abe2009ClinicalAI,
  title={Clinical and immunological evaluation of zoledronate-activated Vgamma9gammadelta T-cell-based immunotherapy for patients with multiple myeloma.},
  author={Yu Abe and Masato Muto and Mie Nieda and Yasunori Nakagawa and Andrew J. Nicol and Touru Kaneko and Shigenori Goto and Kiyoshi Yokokawa and Kenshi Suzuki},
  journal={Experimental hematology},
  year={2009},
  volume={37 8},
  pages={956-68}
}
OBJECTIVE To evaluate the potential anti-tumor activity of zoledronate-activated Vgamma9gammadelta T cells in vivo, we initiated a pilot study involving administration of zoledronate-activated Vgamma9gammadelta T lymphocyte-activated killer (LAK) cells to patients with multiple myeloma. MATERIALS AND METHODS Subjects (n = 6) received four intravenous infusions at 2-week intervals of zoledronate-activated Vgamma9gammadelta T LAK cells generated from the culture of peripheral blood mononuclear… CONTINUE READING